文献速递慢性肾脏病

维生素D补充对CKD患者血管功能的随机试验

A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.
PubMed 文献 · J Am Soc Nephrol · 2017-06-30

这项随机双盲安慰剂对照试验纳入120例18-70岁非糖尿病CKD 3-4期且血清25-羟维生素D≤20 ng/ml的患者,按1:1随机接受两次胆钙化醇300,000 IU口服或安慰剂(基线与第8周)。第16周时补充组内皮依赖性肱动脉血流介导扩张显著改善,组间平均变化差5.49%(95%CI 4.34%-6.64%,P<0.001),脉搏波速度与循环IL-6亦出现有利变化。

要点

  • 非糖尿病CKD 3-4期伴维生素D缺乏者,胆钙化醇可改善内皮依赖性血流介导扩张。
  • 第16周血流介导扩张组间平均变化差5.49%(95%CI 4.34%-6.64%,P<0.001)。
  • 脉搏波速度与循环IL-6水平亦出现显著有利变化。

核心结论

  • 在非糖尿病CKD 3-4期伴维生素D缺乏患者中,维生素D补充可能改善血管功能。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入120例18-70岁非糖尿病CKD 3-4期且血清25-羟维生素D≤20 ng/ml患者。
  • 按1:1随机分配,基线与第8周各接受一次直接观察下口服胆钙化醇300,000 IU或匹配安慰剂。
  • 主要结局为第16周内皮依赖性肱动脉血流介导扩张的变化。

主要发现

  • 第16周血流介导扩张组间平均变化差为5.49%(95%CI 4.34%-6.64%,P<0.001),补充组显著增加而安慰剂组未增加。
  • 干预还使脉搏波速度与循环IL-6水平出现显著有利变化。

关键数值与推荐

  • 维生素D缺乏定义为血清25-羟维生素D≤20 ng/ml。
  • 胆钙化醇剂量为300,000 IU,基线与第8周各一次口服。
  • 主要结局评估时点为第16周。

临床怎么用

  • 对非糖尿病CKD 3-4期合并维生素D缺乏患者,可考虑补充胆钙化醇以改善血管功能指标。
  • 疗效评估可关注血流介导扩张、脉搏波速度及IL-6等血管功能与炎症指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitamin D deficiency associates with mortality in patients with CKD, and vitamin D supplementation might mitigate cardiovascular disease risk in CKD. In this randomized, double-blind, placebo-controlled trial, we investigated the effect of cholecalciferol supplementation on vascular function in 120 patients of either sex, aged 18-70 years, with nondiabetic CKD stage 3-4 and vitamin D deficiency (serum 25-hydroxyvitamin D ≤20 ng/ml). We randomized patients using a 1:1 ratio to receive either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and 8 weeks. The primary outcome was change in endothelium-dependent brachial artery flow-mediated dilation at 16 weeks. Secondary outcome measures included changes in pulse wave velocity and circulating biomarkers. Cholecalciferol supplementation significantly increased endothelium-dependent brachial artery flow-mediated dilation at 16 weeks, whereas placebo did not (between-group difference in mean change: 5.49%; 95% confidence interval, 4.34% to 6.64%; P<0.001). Intervention also led to significant favorable changes in pulse wave velocity and circulating IL-6 levels. Thus, in nondiabetic patients with stage 3-4 CKD and vitamin D deficiency, vitamin D supplementation may improve vascular function. This study is registered with the Clinical Trials Registry of India (no.: CTRI/2013/05/003648).

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kumar V, Yadav AK, Lal A, et al. A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. J Am Soc Nephrol. 2017. PMID: 28667080. doi:10.1681/ASN.2017010003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。